Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00141518
Status:
COMPLETED
Last Update Posted:
2016-07-18
First Post:
2005-08-30
Brief Title:
Long-term Study of Duodopa LevodopaCarbidopa in Advanced Parkinsons Health Outcomes Net Economic Impact
Sponsor:
AbbVie prior sponsor Abbott
Organization:
AbbVie
Study Overview
Official Title:
A Long-term Health Economics Study of Intraduodenal Levodopa Duodopa in Routine Care for Patients With Advanced Idiopathic Parkinsons Disease With Severe Motor Fluctuations and Hyper-Dyskinesia
Status:
COMPLETED
Status Verified Date:
2016-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DAPHNE
Brief Summary:
The primary objective of this study is to collect health economic data depicting the initial levels and natural progression over time of resource usage Parkinsons disease PD-related costs and health related quality of life HRQoL for a cohort of advanced PD patients treated with Duodopa levodopa-carbidopa in an intestinal gel formulation of which about one-third were Duodopa-naïve prior to the start of the study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2005-002654-21 | EUDRACT_NUMBER | None | None |